Timothy A Yap
University of Texas MD Anderson Cancer Center LAO · M.D. Anderson Cancer Center · The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Timothy A Yap as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05327010 · Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET TrialNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · principal investigator
- Ph1NCT05039801 · IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsM.D. Anderson Cancer Center · recruiting · Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm · principal investigator
- Ph1NCT05010096 · BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid TumorsM.D. Anderson Cancer Center · withdrawn · Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1NCT04729725 · SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIALM.D. Anderson Cancer Center · terminated · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · principal investigator
- Ph1NCT04693468 · Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialM.D. Anderson Cancer Center · recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm · principal investigator
- Ph1/Ph2NCT04497116 · Study of RP-3500, Camonsertib, in Advanced Solid TumorsRepare Therapeutics · completed · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT04317105 · Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · principal investigator
- Ph1/Ph2NCT04266912 · Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid TumorsM.D. Anderson Cancer Center · active not recruiting · Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · principal investigator
- Ph1NCT04197713 · Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm · principal investigator
- Ph1NCT03842228 · Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected MutationsNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm · principal investigator
- Ph1NCT03291938 · IACS-010759 in Advanced CancersM.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 · principal investigator
- Ph1NCT02338622 · Trial of Olaparib in Combination With AZD5363 (ComPAKT)Royal Marsden NHS Foundation Trust · completed · Advanced Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitorsR01CA255074 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2025 · $370,575 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT03291938
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:45 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- 2,983 citationsRCR 62.9
- Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.J Clin Oncol · 2010805 citationsRCR 16.9
- Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.J Clin Oncol · 2008735 citationsRCR 17.2
- First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol · 2011476 citationsRCR 11.0
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.J Clin Oncol · 2010293 citationsRCR 6.4
- Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.Clin Cancer Res · 2007225 citationsRCR 4.7
- Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.J Clin Oncol · 2020222 citationsRCR 8.1
- A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.Clin Cancer Res · 2008196 citationsRCR 4.0
- Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.J Clin Oncol · 2011181 citationsRCR 4.4